Filing Flows › Companies › Acadia Pharmaceuticals › Timeline
Acadia Pharmaceuticals stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−2.0% to $21.23
Acadia Pharmaceuticals (ACAD) stock fell 2% over the last 252 sessions, to $21.23. On the way it reported 4 quarters, its insiders filed 18 open-market trades and 2 Form 144 notices of planned sales, and the company filed 4 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 4, 2026 | Earnings | Earnings: beat the EPS estimate by 69.9% | +4.3% (+2.6% vs SPY) | — | — |
| Oct 30, 2026 | Insider sale | Schneyer Mark C. sold $69K | −0.8% (+1.0% vs SPY) | +2.3% (+7.1% vs SPY) | — |
| Oct 23, 2026 | 8-K | Directors and officers: departures, appointments, pay | 0.0% (−0.7% vs SPY) | +4.3% (+4.8% vs SPY) | — |
| Aug 5, 2026 | Form 144 | Form 144: Mark C. Schneyer plans to sell $159K | +5.9% (+6.1% vs SPY) | +8.0% (+8.1% vs SPY) | +6.4% (+7.2% vs SPY) |
| Aug 4, 2026 | Earnings | Earnings: beat the EPS estimate by 317.2% | +5.8% (+4.0% vs SPY) | +13.8% (+11.8% vs SPY) | +12.1% (+11.5% vs SPY) |
| Jul 30, 2026 | Insider sale | Thompson Elizabeth H.Z. sold $433K | +0.8% (−0.9% vs SPY) | +8.9% (+3.5% vs SPY) | +12.1% (+6.6% vs SPY) |
| Jun 26, 2026 | Form 144 | Form 144: James Kihara plans to sell $297K | +6.5% (+7.3% vs SPY) | +9.1% (+7.6% vs SPY) | +6.8% (+6.1% vs SPY) |
| May 29, 2026 | 8-K | Directors and officers: departures, appointments, pay | −0.6% (−0.9% vs SPY) | −0.5% (+2.1% vs SPY) | +15.5% (+16.6% vs SPY) |
| May 26, 2026 | Insider sale | Kihara James sold $114K | +0.8% (+0.1% vs SPY) | +2.0% (+0.3% vs SPY) | +10.2% (+11.6% vs SPY) |
| May 6, 2026 | Earnings | Earnings: missed the EPS estimate by -75.2% | −4.0% (−5.3% vs SPY) | −2.9% (−4.8% vs SPY) | −2.9% (−7.4% vs SPY) |
| May 4, 2026 | Insider sale | Schneyer Mark C. sold $76K | +1.1% (+1.5% vs SPY) | +2.0% (−0.3% vs SPY) | −4.9% (−10.2% vs SPY) |
| May 4, 2026 | Insider sale | Kihara James sold $29K | +1.1% (+1.5% vs SPY) | +2.0% (−0.3% vs SPY) | −4.9% (−10.2% vs SPY) |
| May 1, 2026 | 8-K | Directors and officers: departures, appointments, pay | +1.1% (+1.5% vs SPY) | +2.0% (−0.3% vs SPY) | −4.9% (−10.2% vs SPY) |
| Apr 7, 2026 | Insider sale | Schneyer Mark C. sold $60K | −1.0% (−1.1% vs SPY) | −3.9% (−8.0% vs SPY) | +0.1% (−9.2% vs SPY) |
| Apr 7, 2026 | Insider sale | Kihara James sold $23K | −1.0% (−1.1% vs SPY) | −3.9% (−8.0% vs SPY) | +0.1% (−9.2% vs SPY) |
| Mar 26, 2026 | Insider sale | Schneyer Mark C. sold $69K | −2.5% (−0.7% vs SPY) | +1.4% (+1.6% vs SPY) | −0.2% (−8.6% vs SPY) |
| Mar 26, 2026 | Insider sale | Kihara James sold $24K | −2.5% (−0.7% vs SPY) | +1.4% (+1.6% vs SPY) | −0.2% (−8.6% vs SPY) |
| Mar 25, 2026 | Insider sale | Thompson Elizabeth H.Z. sold $74K | +4.9% (+4.3% vs SPY) | +6.0% (+6.4% vs SPY) | +5.3% (−2.8% vs SPY) |
| Mar 25, 2026 | Insider sale | Schneyer Mark C. sold $90K | +4.9% (+4.3% vs SPY) | +6.0% (+6.4% vs SPY) | +5.3% (−2.8% vs SPY) |
| Mar 25, 2026 | Insider sale | Rhodes Jennifer J sold $83K | +4.9% (+4.3% vs SPY) | +6.0% (+6.4% vs SPY) | +5.3% (−2.8% vs SPY) |
| Mar 25, 2026 | Insider sale | Owen Adams Catherine sold $250K | +4.9% (+4.3% vs SPY) | +6.0% (+6.4% vs SPY) | +5.3% (−2.8% vs SPY) |
| Mar 25, 2026 | Insider sale | Kihara James sold $18K | +4.9% (+4.3% vs SPY) | +6.0% (+6.4% vs SPY) | +5.3% (−2.8% vs SPY) |
| Mar 5, 2026 | 8-K | Directors and officers: departures, appointments, pay | −1.1% (+0.2% vs SPY) | −5.2% (−2.9% vs SPY) | −0.4% (+2.7% vs SPY) |
| Feb 25, 2026 | Earnings | Earnings: missed the EPS estimate by -4.2% | +1.5% (+0.7% vs SPY) | −8.9% (−7.9% vs SPY) | −11.1% (−6.8% vs SPY) |
| Feb 9, 2026 | Insider sale | Rhodes Jennifer J sold $162K | −1.4% (−1.9% vs SPY) | −6.7% (−5.4% vs SPY) | −4.4% (−2.5% vs SPY) |
| Nov 18, 2025 | Insider sale | Schneyer Mark C. sold $243K | −0.9% (0.0% vs SPY) | −0.5% (−0.9% vs SPY) | +11.5% (+10.6% vs SPY) |
| Nov 18, 2025 | Insider sale | Kihara James sold $97K | −0.9% (0.0% vs SPY) | −0.5% (−0.9% vs SPY) | +11.5% (+10.6% vs SPY) |
| Nov 10, 2025 | Insider sale | Daly James M sold $671K | −1.6% (−3.2% vs SPY) | +6.2% (+6.1% vs SPY) | +17.5% (+15.7% vs SPY) |
Insiders’ record here
In the year on the chart, Acadia Pharmaceuticals' insiders reported 0 open-market buys ($0) and 18 sales ($2.6M). Of the 17 old enough to score, 10 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −3.6%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Acadia Pharmaceuticals: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.